K74.0 K74.1 K74.2 K74.3 K74.4 K74.5 K74.6 K70.2 K70.3 K71.7
Conditions
Interventions
Group 1: Study participants are being screened for elevated liver enzymes ALT and AST. If ALT and/or AST are elevated, liver fibrosis risk is estimated using the AST-/platelet ratio index (APRI). Part
Sponsors
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: - Member of the statutory health insurer AOK Rhineland-Palatinate/Saarland - Age = 35 years - Eligible for check-up 35 health check - Informed consent
Exclusion criteria
Exclusion criteria: - Not able to give informed consent - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective is the number of diagnosis of relevant liver fibrosis or liver cirrhosis by using the SEAL-algorithm per 10.000 check-up 35 health checks in comparison with 10.000 historical check-up 35 health checks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives: - prevalence of liver enzyme elevation in the general population - prevalence of chronic liver disease in the general population - number needed to screen - estimation of cost of liver screening - complications and costs within the initial 3 and 12 months after diagnosis of liver fibrosis and cirrhosis by using the SEAL-algorithm compared to patients diagnosed without liver screening - estimation of costs saved by early diagnosis | — |
Countries
Germany
Contacts
Public ContactAnita Arslanow
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität MainzI. Medizinische Klinik und Poliklinik
Outcome results
None listed